New Methylation Profiling Assay for Liquid Biopsy
mDETECT and Thermo Fisher Scientific launched a research assay for cancer detection via methylation profiling of circulating tumor DNA (ctDNA) in blood samples. The Ion AmpliSeq HD Lung Cancer cfDNA Methylation Assay combines mDETECT's methylation analysis with Thermo Fisher's Ion AmpliSeq HD technology. Biodesix will evaluate the assay for lung cancer diagnostics. The assay is for research use only, not yet for diagnostics.
How this was made

The 30-second read
Why it matters
The collaboration introduces a new research tool that could enhance early‑stage cancer monitoring but remains pre‑clinical.
Market read
Introduces a niche research assay that may incrementally benefit Thermo Fisher and Biodesix, with limited immediate market move.
What to watch
Regulatory clearance timelines and the need for clinical validation could delay revenue impact.
Background
Thermo Fisher and mDETECT partner to combine methylation enrichment with Ion AmpliSeq HD technology for lung cancer cfDNA analysis.
Ticker impact
Thermo Fisher Scientific announced a new methylation profiling liquid biopsy assay, the first public disclosure of this product.
likely slight upward pressure as investors price in incremental revenue from the assay.
The assay targets a niche research market; impact depends on adoption by partners like Biodesix.
Biodesix will evaluate the new Thermo Fisher methylation assay in collaboration, marking its first involvement with this technology.
possible modest upside as the partnership could expand Biodesix's service offerings.
Biodesix gains early access to a novel assay, but commercial impact is uncertain at this stage.
Market effects
Could stimulate interest in liquid biopsy and methylation‑based diagnostics across the biotech sector.
Primarily U.S. research market; limited immediate global effect.
Modest, as the assay is research‑focused rather than a commercial diagnostic.
Counterpoint
The assay may face slow adoption due to competition from existing ctDNA platforms and uncertain reimbursement pathways.
Key entities
- CompanyThermo Fisher Scientific
US‑listed provider of scientific instruments and reagents.
- CompanymDETECT
Private firm specializing in methylation‑based diagnostics.
- CompanyBiodesix
US‑listed clinical diagnostics company evaluating the assay.


